Global Market Entry Zelira is actively expanding offices in the United States, Australia, and Germany, reflecting a multi-market growth strategy in the global cannabinoid medicine sector. This creates opportunities for regulatory, distribution, and local market access partners to accelerate market entry.

Clinical Collaboration Opportunities With ZLT-L-007 advancing in neuropathic pain and a recent multi-arm head-to-head study against Lyrica, plus a CRO partnership with Affinity Bio Partners, there are clear openings for licensing, co-development, or research collaborations in analgesic programs and related neurology indications.

Strategic Financing A US$33 million funding deal via the HOPE 1 SPV signals strong financial backing and potential for milestone-based partnerships, co-development funding, or licensing arrangements to scale the pipeline.

Leadership Networking Strategic governance, highlighted by the appointment of a seasoned non-executive director, can facilitate introductions to pharma and investor networks, supporting partnership negotiations and governance-ready collaborations.

Lean Outsourcing Model With a small headcount, Zelira already relies on external CROs, CMOs, and trial partners. This suggests high receptivity to outsourcing arrangements for clinical operations, manufacturing, regulatory affairs, and distribution as the company scales.